Web Exclusives

CheckMate 649 study results demonstrate that nivolumab combined with chemotherapy has an acceptable safety profile and improves survival outcomes in patients with advanced gastric/esophageal cancer. Read More ›

Japanese study data demonstrate second-line pembrolizumab improved overall survival with an acceptable safety profile compared with chemotherapy in patients with advanced esophageal cancer. Read More ›

An expert panel released recommendations for the clinical management of patients with advanced esophageal cancer and gastroesophageal junction adenocarcinoma. Read More ›

Nivolumab added to either ipilimumab or chemotherapy improved overall survival in patients with advanced esophageal squamous-cell carcinoma, according to data from the CheckMate-648 study. Read More ›

A comprehensive analysis of immune checkpoints in gastric adenocarcinoma found that ICOSLG and CD70 are associated with immune infiltration and may potentially serve as prognostic biomarkers. Read More ›

Phase 2 study results of second-line trastuzumab deruxtecan use in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer revealed an antitumor response. Read More ›

Researchers reported that molecular testing in patients with non–small-cell lung cancer aged ≥70 years is performed at the same proportions as in younger patients. Read More ›

Analysis of EGFR, KRAS, and PIK3CA gene mutation rates in patients with lung cancer revealed a correlation with clinical characteristics that may have a significant effect on personalized cancer treatment. Read More ›

A recently released report indicates that low-dose computed tomography targeted screening for lung cancer confers patient health and public health benefits. Read More ›

A large cohort analysis of treatment status, treatment regimen, and outcomes in patients with KRAS-mutated advanced NSCLC revealed valuable information for future clinical trials. Read More ›

Page 3 of 42

Subscribe to The Oncology Nurse-APN/PA

To sign up for our newsletter or print publications, enter your contact information below.

I'd like to receive: